22 September 2009
Sinclair Pharma plc ("Sinclair Pharma" or the "Company")
Statement regarding share price movement
The Board of Sinclair Pharma notes the recent movement in the Company's share
price and announces that it is currently in discussions about a potential
significant product acquisition. The Company would expect to fund this
acquisition substantially through an equity fundraising and it would be subject
to shareholder approval.
These discussions are ongoing and there is no certainty about the final outcome.
A further announcement will be made in due course as and when necessary.
Enquiries
For further information please contact:
Sinclair Pharma plc - Tel: +44 (0)1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Capital MS&L - Tel +44 (0)20 7307 5340
Mary Clark
Anna Mitchell
Singer Capital Markets - Tel: +44 (0)20 3205 7500
Shaun Dobson
Claes Spång
http://www.sinclairpharma.com/